Allarity Therapeutics Inc (ALLR)

$1.17 -0.02 (-1.68%)
Market Cap 18.93M
Revenue (ttm) 320,000.00
Net Income (ttm) -11.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,509.37%
Debt to Equity Ratio 0.21
Volume 51,560
Avg Vol 205,488
Day's Range N/A - N/A
Shares Out 15.91M
Stochastic %K 79%
Beta 0.53
Analysts Sell
Price Target $10.25

Company Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a...

Industry: Biotechnology
Sector: Healthcare
Phone: 401 426 4664
Address:
123 E. Tarpon Ave., Tarpon Springs, United States
Popsiclestick
Popsiclestick Jul. 20 at 6:40 PM
$ALLR
0 · Reply
biotrade123
biotrade123 Jul. 20 at 3:15 PM
$ALLR
0 · Reply
selftaught
selftaught Jul. 17 at 4:14 PM
$ALLR lets see if picking up more at 1.20 will pay off
1 · Reply
selftaught
selftaught Jul. 17 at 3:54 PM
$ALLR If this finally going to take off?
1 · Reply
BioRich
BioRich Jul. 16 at 8:39 PM
$GUTS Still massively bullish. #1 on our list and that doesn't appear to be changing anytime soon. Surprisingly, adding more on this pullback. Simple math...this kicks to a buck again (which I have no doubt it will...and beyond), you're up 17% on your trade. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI $ALLR $ALUR $VERU
3 · Reply
Wody
Wody Jul. 16 at 8:24 PM
$ALLR low volume day, all buying and we drop? Some shady shit going on…
0 · Reply
selftaught
selftaught Jul. 16 at 2:48 PM
$ALLR Wanting more at 1.13 if possible.
1 · Reply
Dizzier47
Dizzier47 Jul. 16 at 9:46 AM
$ALLR when this reaches 50 I'll take a two month vacation in Denmark
0 · Reply
rexwiggins
rexwiggins Jul. 16 at 8:36 AM
$ALLR $AMCOF buying both now
0 · Reply
Zynth
Zynth Jul. 14 at 7:59 PM
$ALLR $FCHL $YYGH $SKYA rgk
0 · Reply
Latest News on ALLR
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Jul 7, 2026, 8:00 AM EDT - 13 days ago

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

Jun 30, 2026, 8:00 AM EDT - 20 days ago

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

Allarity to present trial-in-progress poster on Phase 2 stenoparib trial

2026-06-18T12:18:06.000Z - 4 weeks ago

Allarity to present trial-in-progress poster on Phase 2 stenoparib trial

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

Jun 18, 2026, 8:00 AM EDT - 4 weeks ago

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

May 15, 2026, 4:30 PM EDT - 2 months ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

May 8, 2026, 8:45 AM EDT - 2 months ago

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

May 5, 2026, 8:00 AM EDT - 2 months ago

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity receives notice of allowance from USPTO

2026-04-27T13:21:02.000Z - 3 months ago

Allarity receives notice of allowance from USPTO

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity closes $20M financing for stenoparib advancement

2026-03-06T13:19:41.000Z - 4 months ago

Allarity closes $20M financing for stenoparib advancement

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Mar 6, 2026, 8:00 AM EST - 4 months ago

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity doses first patients in Phase 2 trial of SCLC

2026-02-18T13:25:56.000Z - 5 months ago

Allarity doses first patients in Phase 2 trial of SCLC

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Feb 18, 2026, 8:15 AM EST - 5 months ago

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide

2026-02-03T13:20:33.000Z - 5 months ago

Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Feb 3, 2026, 8:00 AM EST - 5 months ago

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Allarity CEO says 2026 represents an ‘inflection point’

2025-12-31T13:05:34.000Z - 7 months ago

Allarity CEO says 2026 represents an ‘inflection point’

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

Dec 31, 2025, 8:00 AM EST - 7 months ago

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

Allarity files $50M mixed securities shelf

2025-12-03T14:15:27.000Z - 8 months ago

Allarity files $50M mixed securities shelf

Allarity reports Q3 EPS (19c) vs ($7.71) last year

2025-11-14T14:06:08.000Z - 8 months ago

Allarity reports Q3 EPS (19c) vs ($7.71) last year

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 9:00 AM EST - 8 months ago

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Allarity files to sell 1.56M shares of common stock for holders

2025-09-25T21:25:29.000Z - 10 months ago

Allarity files to sell 1.56M shares of common stock for holders

Allarity presents new Phase 2 clinical data for Stenoparib

2025-09-22T12:20:54.000Z - 10 months ago

Allarity presents new Phase 2 clinical data for Stenoparib

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Sep 22, 2025, 8:00 AM EDT - 10 months ago

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

Sep 17, 2025, 8:00 AM EDT - 10 months ago

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?

2025-08-27T01:00:00.000Z - 11 months ago

Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?

Allarity announces FDA granted Fast Track designation to stenoparib

2025-08-26T12:05:59.000Z - 11 months ago

Allarity announces FDA granted Fast Track designation to stenoparib

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Aug 26, 2025, 8:00 AM EDT - 11 months ago

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

Aug 15, 2025, 4:30 PM EDT - 1 year ago

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

Allarity initiated with a Buy at Ascendiant

2025-07-28T09:50:42.000Z - 1 year ago

Allarity initiated with a Buy at Ascendiant

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

Allarity appoints Jeff Ervin as CFO

2025-07-07T12:26:02.000Z - 1 year ago

Allarity appoints Jeff Ervin as CFO

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Allarity gets Australian patent acceptance notice for DRP companion diagnostic

2025-06-30T14:34:35.000Z - 1 year ago

Allarity gets Australian patent acceptance notice for DRP companion diagnostic

Allarity announces second patient dosed in Phase 2 trial of stenoparib

2025-06-27T12:10:38.000Z - 1 year ago

Allarity announces second patient dosed in Phase 2 trial of stenoparib

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Changes to Board of Directors

Jun 11, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Announces Changes to Board of Directors

Allarity announces research collaboration with IBRI

2025-06-04T12:05:09.000Z - 1 year ago

Allarity announces research collaboration with IBRI

Allarity announces first patient enrolled in Phase 2 trial of stenoparib

2025-06-02T12:30:27.000Z - 1 year ago

Allarity announces first patient enrolled in Phase 2 trial of stenoparib

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

May 9, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Mar 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Feb 24, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Feb 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Jan 30, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Nov 18, 2024, 8:00 AM EST - 1 year ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Popsiclestick
Popsiclestick Jul. 20 at 6:40 PM
$ALLR
0 · Reply
biotrade123
biotrade123 Jul. 20 at 3:15 PM
$ALLR
0 · Reply
selftaught
selftaught Jul. 17 at 4:14 PM
$ALLR lets see if picking up more at 1.20 will pay off
1 · Reply
selftaught
selftaught Jul. 17 at 3:54 PM
$ALLR If this finally going to take off?
1 · Reply
BioRich
BioRich Jul. 16 at 8:39 PM
$GUTS Still massively bullish. #1 on our list and that doesn't appear to be changing anytime soon. Surprisingly, adding more on this pullback. Simple math...this kicks to a buck again (which I have no doubt it will...and beyond), you're up 17% on your trade. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI $ALLR $ALUR $VERU
3 · Reply
Wody
Wody Jul. 16 at 8:24 PM
$ALLR low volume day, all buying and we drop? Some shady shit going on…
0 · Reply
selftaught
selftaught Jul. 16 at 2:48 PM
$ALLR Wanting more at 1.13 if possible.
1 · Reply
Dizzier47
Dizzier47 Jul. 16 at 9:46 AM
$ALLR when this reaches 50 I'll take a two month vacation in Denmark
0 · Reply
rexwiggins
rexwiggins Jul. 16 at 8:36 AM
$ALLR $AMCOF buying both now
0 · Reply
Zynth
Zynth Jul. 14 at 7:59 PM
$ALLR $FCHL $YYGH $SKYA rgk
0 · Reply
Popsiclestick
Popsiclestick Jul. 14 at 6:21 PM
$ALLR
0 · Reply
biotrade123
biotrade123 Jul. 14 at 5:01 PM
$ALLR algos need to very carefully take this up as this is a retail play, any pop will result in retail bagholders dumping and tanking it again, badly need institutional share for sustained upside.
0 · Reply
Wody
Wody Jul. 14 at 11:11 AM
$ALLR
0 · Reply
Dizzier47
Dizzier47 Jul. 14 at 8:32 AM
$ALLR when this reaches 30$ ill buy a danish flag
1 · Reply
JuggernautRaider
JuggernautRaider Jul. 13 at 4:36 PM
i'm a sick puppy... i love my $BMY shares, or "pharma bonds" as my friends call them... but I sold a bunch to buy $TNXP $TLSA and $ALLR ... the prices are too cheap, the spreads are too juicy, and The Bonesaw of Biotech is THIRSTY!!! 🍖❤️🍹
1 · Reply
JuggernautRaider
JuggernautRaider Jul. 13 at 1:49 PM
$ALLR buying dips, selling peaks, buy the dip, sell the peak... their PPS management to avoid @nasdaq_crazy delisting is something to behold! They know the difference between $1 and $5 (the supposed penny stock cutoff!)
0 · Reply
Wody
Wody Jul. 13 at 12:10 PM
$ALLR
0 · Reply
gms888777777
gms888777777 Jul. 10 at 5:43 PM
$ALLR who's dumping blocks nonstop every day unreal..
1 · Reply
selftaught
selftaught Jul. 10 at 2:20 PM
$RIG and $SDRL looking good.$UAMY seems to be floundering at the moment. Waiting to see where it wants to go. $ALLR still showing higher lows. but might flip to reduce risk and cost basis. This week shows that calls may not always pan out but you must have a plan if it goes the opposite way and you have to be okay with that. Don't get stuck in inaction. Sometimes de-risking and sitting on the sidelines can be the best play.
0 · Reply
selftaught
selftaught Jul. 10 at 2:15 PM
$ALLR Might flip it to reduce my cost basis
0 · Reply
selftaught
selftaught Jul. 10 at 2:07 PM
$ALLR Sold half to reduce risk at 1.20
0 · Reply
biotrade123
biotrade123 Jul. 9 at 10:37 PM
$ALLR slowly and delicatelty pulled up by algos by limiting vol as any spike in vol could result in retail dump crashing it back, this is what happens when there hardly any institutional holders.
0 · Reply